Scheme 1A - HLA Phenotyping 0 out of 5 distributions remaining | |
Scheme 1B - HLA-B27 Testing 0 out of 5 distributions remaining | |
Scheme 2A - Cytotoxic Crossmatching 0 out of 5 distributions remaining | |
Scheme 2B - Crossmatching by Flow Cytometry 0 out of 5 distributions remaining | |
Scheme 3 - HLA Antibody Specificity Analysis 0 out of 3 distributions remaining | |
Scheme 4A1 - HLA Typing at 1st Field Resolution 0 out of 3 distributions remaining | |
Scheme 4A2 - HLA Typing to 2nd or 3rd Field Resolution 0 out of 3 distributions remaining | |
Scheme 5A - HFE Typing 0 out of 3 distributions remaining | |
Scheme 5B - Interpretative: HFE Genotype and HH 0 out of 2 distributions remaining | |
Scheme 6 - HLA Antibody Detection 0 out of 3 distributions remaining | |
Scheme 7 - HLA-B*57:01 Typing for Drug Hypersensitivity 0 out of 3 distributions remaining | |
Scheme 8 - HLA Genotyping for Coeliac and other HLA associated diseases 0 out of 3 distributions remaining | |
Scheme 9 - KIR Genotyping 0 out of 2 distributions remaining | |
Scheme 10 - HPA Genotyping 0 out of 2 distributions remaining | |
Scheme 11 - HPA Antibody Detection/Specification 0 out of 2 distributions remaining | |
ED - Educational HLA Typing 0 out of 2 distributions remaining | |
iED - Interpretive Clinical Scenarios 0 out of 3 distributions remaining | |
EDXM - Educational Combined Crossmatch/HLA Type/Antibody analysis 0 out of 1 distributions remaining | |
